摘要
目的探究莫西沙星联合头孢哌酮舒巴坦治疗重症监护室(ICU)患者多重耐药菌感染的效果及安全性。方法选择2019年1月至2020年1月漯河市中医院收治的90例多重耐药菌感染的ICU患者作为研究对象,根据随机抽签原则分为对照组(给予头孢哌酮舒巴坦治疗)和研究组(在对照组的基础上联用莫西沙星治疗),每组均为45例。观察两组体征以及临床症状恢复时间,观察两组治疗后临床疗效有效率以及细菌清除率,对比两组治疗前、治疗14 d后血清肿瘤坏死因子-α(TNF-α)与降钙素原(PCT)水平,观察两组治疗过程中不良反应发生情况。结果研究组的胸部X线平片恢复正常时间(12.43±4.51)d、体温恢复正常时间(3.25±1.32)d、肺部啰音消失时间(7.39±2.15)d以及白细胞计数恢复正常时间(3.84±1.57)d均比对照组的胸部X线平片恢复正常时间(15.62±5.74)d、体温恢复正常时间(5.59±1.83)d、肺部啰音消失时间(11.26±2.97)d以及白细胞计数恢复正常时间(6.98±2.45)d短(P<0.05)。研究组治疗后临床疗效有效率明显比对照组高(98.56%VS77.78%,P<0.05)、研究组细菌清除率明显比对照组高(88.89%VS68.89%,P<0.05)。治疗前,两组的血清TNF-α、PCT水平比较无显著性差异(P>0.05);治疗14 d后,两组的血清TNF-α、PCT水平均比治疗前低(P<0.05),且研究组比对照组低(P<0.05)。研究组治疗过程中不良反应发生率比对照组略高(17.78%VS13.33%,P>0.05)。结论对多重耐药菌感染的ICU患者采用莫西沙星联合头孢哌酮舒巴坦治疗,可缩短患者体征以及临床症状恢复时间,提高临床疗效有效率,提高细菌清除率,可减轻机体的炎症反应,且具有一定的安全性。
Objective To explore the efficacy and safety of moxifloxacin combined with cefoperazone and sulbactam in the treatment of multi-drug-resistant bacterial infections in intensive care unit(ICU)patients.Methods A total of 90 ICU patients with multi-drug resistant bacteria who were admitted to our hospital from January 2019 to January 2020 were selected as the research objects.According to the principle of random drawing,they were divided into a control group(treated with cefoperazone and sulbactam)and a study group(treated with moxifloxacin on the basis of the control group),with 45 cases in each group.Two groups of signs and clinical symptoms recovery time were observed.The clinical efficacy and bacterial clearance rate of the 2 groups after treatment were observed.The serum tumor necrosis factor-α(TNF-α)and procalcitonin(PCT)levels were compared before and 14 days after treatment in the two groups.The occurrence of adverse reactions during the treatment of the 2 groups was observed.Results The study group’s chest X-ray plain film returned to normal time(12.43±4.51)d,body temperature returned to normal time(3.25±1.32)d,lung rales disappeared time(7.39±2.15)d,and white blood cell count returned to normal time(3.84±1.57)d were all compared with the control group’s chest X-ray plain film recovery time(15.62±5.74)d,body temperature return to normal time(5.59±1.83)d,lung rales disappearance time(11.26±2.97)d and white blood cell count recovery normal time(6.98±2.45)d was low(P<0.05).The effective rate of clinical efficacy in the study group after treatment was significantly higher than that of the control group(98.56%VS77.78%,P<0.05),and the bacterial clearance rate of the study group was significantly higher than that of the control group(88.89%VS68.89%,P<0.05).Before treatment,there was no significant difference in serum TNF-αand PCT levels between the two groups(P>0.05).After 14 days of treatment,serum TNF-αand PCT levels in the two groups were lower than before treatment(P<0.05),and the study group w
作者
胡芸芸
HU Yunyun(Department of ICU,Luohe Hospital of traditional Chinese Medicine,Luohe Henan 462000,China)
出处
《临床研究》
2021年第12期8-11,共4页
Clinical Research
关键词
莫西沙星
头孢哌酮舒巴坦
多重耐药菌感染
ICU患者
安全性
Moxifloxacin
cefoperazone and sulbactam
multi-drug resistant bacteria infection
ICU patients
safety
